Swiss Startups in Boston Ahead of BIO 2024

As part of the Innosuisse Internationalization Camps, four Swiss biotech startups will explore the Boston ecosystem on their way to the BIO International Convention in San Diego.

May 14, 2024 | Boston

From May 29 to 31, four Swiss biotech startups will travel to Boston to explore the world’s leading biotech ecosystem, learn about different regulatory aspects of US market entry, and connect with local entrepreneurs and investors as part of their experience in the Innosuisse Internationalization Camps run by Swissnex. Over three days, the startups will gain insight on topics including incorporation, financing, pitching, negotiation, taxation, hiring, and FDA approval from local experts. In addition, they will have the opportunity to make connections with representatives from leading Boston-area biotech and pharma firms at several events, including Swissnex’s garden party with Boston-based attendees of the BIO International Convention 2024 (BIO 2024).

From June 3 to 6, the startups will travel to San Diego for BIO 2024, where the official Swiss presence is anchored by the Swiss Biotech Pavilion, organized by Switzerland Global Enterprise in close collaboration with the Swiss Biotech Association, the Swiss Business Hub USA, the Swiss Innovation Agency Innosuisse, and Swissnex. The convention, which attracts over 15,000 biotechnology and pharma leaders representing a wide spectrum of life science research and applications, will offer the startups the opportunity to expand their international networks, discover trends, and identify new opportunities and promising partnerships in the US and across the globe. This year, the Swiss Biotech Pavilion will host more than 40 exhibitors, a strong follow-up to the presence at the 2023 convention in Boston, during which the pavilion hosted a record number of 49 exhibitors.

The four Swiss startups traveling to Boston in advance of BIO 2024 are:

  • Nagi Bioscience | Nagi’s SydLab System is a benchtop laboratory device allowing standardized drug and chemical testing on microorganisms within disposable microfluidic cartridges.
  • mimiX biotherapeutics | FastSkin, a dermal substitute developed by mimiX using their Sound Induced Morphogenesis technology, offers a novel solution to help patients struggling to heal from complex wounds.
  • Cellestia | Cellestia is a fully integrated R&D company specialized in innovative therapeutics with new modes of action to treat autoimmune diseases and multidrug resistant cancers.
  • Amphilix | Amphilix is developing small molecular chimeras utilizing a unique linker platform that enables fine-tuning of molecular properties, raising the bar for standard-of-care treatment and addressing unmet medical needs.